Clinical trials: Glomerulonephritis
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus…
- Trial name
- REGENCY (NCT04221477)
- Testing
- Obinutuzumab, MMF, Prednisone
- Where
- 74 sites in United States, Argentina and 13 more
- Volunteers
- 271 people
- Sponsor
- Hoffmann-La Roche
IgA Nephropathy
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Efficacy and safety of LNP023 in IgAN patients
- Trial name
- NCT03373461
- Testing
- LNP023
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy (IgAN), Renal and Urinary Disorders
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
The purpose of this study is to collect long-term safety and tolerability data for atacicept in patients with IgAN that completed Vera trial investigating atacicept in IgAN population.
- Conditions
- IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
- Trial name
- ORIGIN EXTEND (NCT06674577)
- Testing
- Atacicept 150 mg
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Vera Therapeutics, Inc.
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Trial name
- NCT03719443
- Testing
- VIS649
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
IGA Nephropathy
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.
- Trial name
- NCT02433236
- Testing
- Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium tablet 150 mg
- Sponsor
- Rigel Pharmaceuticals
IgA Nephropathy
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases
- Trial name
- NCT06774664
- Testing
- SCTC21C
- Where
- 20 sites in China
- Volunteers
- 99 people
- Sponsor
- Sinocelltech Ltd.
Idiopathic Membranous Nephropathy
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
This was a randomized, open-label, two arm, parallel group, proof-of-concept, nonconfirmatory study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with Idiopathic (primary) membranous nephropathy…
- Trial name
- NCT04154787
- Testing
- LNP023, Rituximab
- Where
- 18 sites in Argentina, China and 7 more
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy, IgAN
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.
- Trial name
- NCT05125068
- Testing
- AT-1501
- Where
- 26 sites in Australia, Croatia and 8 more
- Volunteers
- 24 people
- Sponsor
- Eledon Pharmaceuticals
Membranous Nephropathy
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN
- Trial name
- NCT04652570
- Testing
- VB119
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Tenet Medicines
IgA Nephropathy
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin…
- Trial name
- NCT05775042
- Testing
- CM338
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Keymed Biosciences Co.Ltd
C3 Glomerulopathy, C3 Glomerulonephritis
A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant…
- Conditions
- C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
- Trial name
- NCT03369236
- Testing
- Danicopan
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Focal Segmental Glomerulosclerosis
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
- Trial name
- NCT03703908
- Testing
- CCX140-B
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Amgen
Primary IgA Nephropathy
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials.
- Trial name
- NCT04557462
- Testing
- LNP023
- Where
- 161 sites in United States, Argentina and 34 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
Focal Segmental Glomerulosclerosis
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
- Trial name
- AURONA™ (NCT03598036)
- Testing
- Voclosporin
- Where
- 23 sites in United States, Dominican Republic
- Volunteers
- 5 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Immunoglobulin A Nephropathy, Glomerular Disease
Safety and Efficacy Study of VIS649 for IgA Nephropathy
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Trial name
- NCT04287985
- Testing
- Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Lupus Erythematosus, Systemic, Lupus Nephritis
Study of LJP 394 in Lupus Patients With History of Renal Disease
The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.
- Trial name
- ASPEN (NCT00089804)
- Testing
- abetimus sodium (LJP 394), Phosphate-buffered saline
- Where
- 201 sites in United States, Argentina and 28 more
- Volunteers
- 943 people
- Sponsor
- La Jolla Pharmaceutical Company
Kidney Diseases, Diabetic Nephropathies
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change…
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid
- Trial name
- NCT04387448
- Testing
- GFB-887
- Where
- 74 sites in United States
- Volunteers
- 96 people
- Sponsor
- Goldfinch Bio, Inc.
IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
The study is being conducted to evaluate the effect of food on pharmacokinetics of HRS-5965 capsules after oral administration.
- Trial name
- NCT07035665
- Testing
- HRS-5965 Capsules
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
IgA Nephropathy
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
The study was designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d.
- Trial name
- APPLAUSE-IgAN (NCT04578834)
- Testing
- LNP023
- Where
- 177 sites in United States, Argentina and 33 more
- Volunteers
- 517 people
- Sponsor
- Novartis Pharmaceuticals